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Introduction
Ernest L. Mazzaferri, M.D., M.A.C.P.
A well-established feature of papillary thyroid carcinoma
(PTC) is it propensity to metastasize to cervical lymph nodes
in the central and lateral compartments. Currently, there is no
non- or minimally invasive method that is completely reliable
for detecting all of the metastases that are present. Therefore,
some have advocated prophylactic cervical lymph node dis-
section as part of the operative procedure for PTC. There is no
unanimity, however, on the efficacy and safety of prophy-
lactic cervical lymph node dissection for this tumor. At the
recent National Thyroid Cancer Workshop II,* two distin-
guished surgeons, Dr. Gerard M. Doherty from the Univer-
sity of Michigan and Dr. David L. Steward at the University
of Cincinnati, were invited to debate the pros and cons of
prophylactic cervical lymph node dissection. More specifi-
cally, Dr. Doherty was asked to take the positive view and
Dr. Steward the contrary view concerning prophylactic cen-
tral compartment (Level VI) dissection (CLND). By definition,
this is a total compartment dissection that is performed when
there is no preoperative or intraoperative evidence of cervical
lymph-node metastases. Each participant was asked to mar-
shal the case for one side and not necessarily reflect their
personal views. To help them prepare, they were given the
following hypothetical case to consider.
A 22-year-old woman is referred by her endocrinologist for
surgical management of an asymptomatic 2-cm PTC diag-
nosed 1 week before. There is no family history of thyroid
cancer, and she has had no exposure to radiation. Her thyroid-
stimulating hormone (TSH) level is 1.7 (IU=mL. Repeat neck
ultrasonography reveals a single 2-cm right lobe thyroid
nodule with a hazy border and no lateral or central neck
lymph-node abnormalities. The question posed to the debat-
ers is: What are the pros and cons of prophylactic level VI
lymph-node dissection for this patient?
After the workshop, these surgeons, who are recognized
authorities on the surgical management of thyroid cancer,
were asked to prepare written commentary based on their
presentations. What follows are two concise, carefully artic-
ulated, literature-based reviews that support each side of the
debate.
Pro
Gerard M. Doherty, MD
Cervical lymph node metastases are common in PTC, oc-
curring in 20% to 50% of patients using standard pathologic
techniques (1). Micrometastases are even more common in
PTC. One series found micrometastases in nearly 90% of ex-
amined nodes (2). Nodal metastases are known to correlate
significantly with the persistence and recurrence of PTC (3).
However, it has traditionally been accepted that regional
lymph node metastases in PTC may increase regional recur-
rence rates but do not ultimately affect survival (4–6), as at-
tested by the omission of regional lymph node metastases in
the AMES,{ AGES,{ and MACIS§ prognostic scoring systems
(7–9). However, among other data, a large population-based
study demonstrating greater mortality associated with re-
gional lymph node metastases (10) has challenged this view.
Hence, there has been a recent focus on the role of operative
management of cervical lymph node metastases during the
initial operation for thyroid cancer (1).
The only area of significant current controversy is the util-
ity of prophylactic CLND. The term ‘‘prophylactic’’ denotes
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removal of lymph nodes that appear normal according to
palpation and imaging studies preoperatively and intra-
operatively. In contrast, ‘‘therapeutic’’ dissection denotes re-
moval of lymph nodes that likely contain metastatic disease
based on palpation or imaging studies. There is universal
agreement that lymph node involvement should always be
assessed using preoperative examination and ultrasound, and
intraoperative inspection, and that evidence of central com-
partment node (Level 6) involvement should prompt thera-
peutic complete dissection of the nodes in that compartment,
rather than ‘‘berry-picking.’’ It is also accepted that prophy-
lactic dissection of the lateral neck compartments (Levels 1–5)
is not necessary, because those compartments of the neck are
not violated during thyroidectomy and so could be dissected
at a later time without increased risk due to the reoperative
field. The important remaining question is whether removal
of normal-appearing nodes from the central compartment
during thyroidectomy has benefit. Some evidence for this has
been extensively catalogued previously (11).
Arguments for Prophylactic Dissection. The rationales for
prophylactic central neck dissection are as follows. Each is
considered, in order, in the following paragraphs.
 Lymph node metastases have a negative effect on pa-
tient outcome.
 Lymph node metastases in the central neck cannot be
reliably identified at operation.
 Meticulous central neck node dissection has a beneficial
effect on subsequent course.
 Central neck dissection can be performed safely.
 Reoperation for central neck recurrence has greater
morbidity.
Nodal metastases have been regarded as innocuous for
patients with PTC, but this turns out not to be true when
studied more carefully. For example, in a recent, carefully
performed retrospective analysis with long patient follow-up,
Swedish investigators demonstrated that lymph node me-
tastases were associated with diminished survival, even when
adjusted for TNM staging (10). In addition, lymph node me-
tastases are associated with a greater risk of locoregional
recurrence (5, 12, 13) in some, but not all, studies (7, 9, 14).
Although the data are conflicting, the existence of excellent
data showing greater risk should outweigh the lack of such a
finding in studies underpowered to identify this.
One strategy to avoid prophylactic dissection is to actively
evaluate the central compartment for metastasis and perform
therapeutic dissection if the nodes are involved. However, the
central compartment nodes cannot be sensitively assessed
uisng preoperative ultrasound examination (14, 15) or in-
traoperative examination (15, 16). Without the ability to reli-
ably identify node metastasis using ultrasound or surgery,
this assessment strategy cannot replace prophylactic dissec-
tion. Actively seeking node involvement to guide the extent of
surgery is preferable, however, if prophylactic dissection is
not chosen routinely.
No prospective, randomized data exist to explain the effect
of CLND on recurrence or disease-specific mortality in PTC.
One prospective Swedish study with contemporaneous con-
trols provides the best available data (17) to support im-
provement in survival. This study details the surgical and
disease outcomes from a prospectively studied group of 195
patients with PTC and compares them with contemporaneous
outcomes from other Scandinavian populations (Norway and
Finland). All patients in the Swedish cohort had meticulous
CLND and radioiodine only if there was substantial cervical
uptake on radioiodine scan; 6% of the patients received
radioiodine. Median follow-up was 13 years, and 37% of the
patients were American Joint Committee on Cancer (AJCC)
stage III, compared with 19% to 28% Stage III and 10- to 11.5-
year median follow-up in the comparison cohorts. Death due
to thyroid cancer occurred in 1.6% of the Göteborg cohort,
compared with 8.4% to 11.1% in the comparison groups. Four
retrospective cohort studies (level IV) also exist (18–21), with
mixed results, with two supporting improvement with node
dissection and two showing no difference. One retrospective
cohort study provides related evidence using thyroglobulin
levels as a surrogate endpoint (22). This study retrospectively
examined 447 patients with clinically node-negative PTC.
Fifty-six patients underwent total thyroidectomy plus ipsi-
lateral CLND, and 391 patients had total thyroidectomy
alone. Both groups had equivalent tumor sizes and MACIS
scores, and both groups were treated with radioactive iodine,
with the mean dose not different between the two groups.
Postablation serum levels of thyroglobulin, a marker for re-
sidual PTC, were lower in those with CLND (p¼ 0.02), and
more patients with CLND had undetectable thyroglobulin
levels (72% ves 43%; p< 0.001). On balance, there is some
evidence to support improvement in outcome by including
dissection, and only underpowered studies that show no
difference.
Operative morbidity is one concern about including rou-
tine prophylactic central neck dissection in thyroid cancer
treatment. Total thyroidectomy without lymph node dissec-
tion performed by surgeons experienced in the procedure
results in permanent hypoparathyroidism in 1% to 2% of
patients and permanent nerve injury (recurrent laryngeal,
external branch of the superior laryngeal) in 1% to 2% of pa-
tients. No high-level evidence exists to define whether the
addition of CLND to total thyroidectomy for PTC confers
greater risk of permanent hypoparathyroidism or permanent
nerve injury. An expert series with liberal use of parathyroid
autotransplantation did not find greater morbidity (22), al-
though other studies are mixed in their information regarding
greater risk of permanent hypoparathyroidism (14, 23–27).
The morbidity appears to be related to surgical skill and ex-
perience, but selected surgeons can safely perform central
node dissection.
One thing that is clear is that reoperation in the central neck
compartment for recurrent PTC has greater risk of hypopa-
rathyroidism and unintentional nerve injury than initial total
thyroidectomy with or without CLND (28–32). This supports
more-aggressive initial surgery in cohorts of patients in whom
central neck recurrence is sufficiently likely to require re-
operation in some fraction if not initially cleared of disease.
Conclusion (Dr. Doherty). The application of prophylac-
tic central neck dissection to patients with differentiated
thyroid cancer (DTC) is a controversial area in thyroid cancer
management. As with many issues regarding the manage-
ment of DTC, there are no level one data to support or refute
the hypothesis that central neck dissection at the time of ini-
tial thyroid cancer treatment is beneficial, but in expert
surgical hands, the addition of central neck node dissection to
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total thyroidectomy should carry no greater patient risk
and probably has benefit for disease-free and possibly overall
survival in patients who are at some risk of recurrence. Fi-
nally, the value of identifying patients who are definitively
node negative is not clear, but dissection may also benefit
them by defining a group that can receive limited or no ad-
juvant therapy and who may require less-intensive follow-up.
Con
David L. Steward, M.D., F.A.C.S.
Treatment decisions necessarily involve a balance of risk to
the patient from disease with risk and benefit to the patient
from its treatment. This balance involves concepts of benefi-
cence and nonmalfeasance, with the latter summed up suc-
cinctly in the Hippocratic Oath, ‘‘primum, non nocerum,’’ or
first, do no harm.
By definition, prophylactic CLND implies removal of
lymph node–bearing tissue from the central compartment in
the absence of clinically detectable nodal metastasis using
all available modalities (preoperative and intraoperative in-
spection, palpation, and imaging). In contrast, a therapeutic
dissection involves removal in the presence of clinically de-
tectable nodal metastasis. The rationale for prophylactic neck
dissection is based upon suspicion of a high incidence of oc-
cult (subclinical) nodal metastasis, often microscopic. How-
ever, the decision to perform prophylactic central neck
dissection can not be justified solely upon the discovery of
subclinical nodal metastasis. Were that sufficient justifica-
tion, then prophylactic lateral compartment neck dissections
should also be performed for every patient with PTC based
upon the known high incidence of occult nodal metastasis in
the lateral compartment as well. In fact, the prognosis of
clinically detectable (macroscopic) nodal metastasis may dif-
fer from clinically occult (microscopic) nodal metastasis (33,
34). As such, justification for prophylactic central neck dis-
section needs to be based upon evidence of patient benefit
exceeding harm. With regard to thyroid carcinoma, clinical
benefit is measured primarily in terms of lower recurrence
and mortality rates, whereas harm is measured in terms of
higher complication rates, including recurrent laryngeal nerve
injury and hypoparathyroidism.
The following careful analysis of the literature on the topic
fails to demonstrate evidence of benefit from prophylactic
central neck dissection. In contrast, it demonstrates clear and
consistent evidence of harm, primarily transient hypopara-
thyroidism. The likelihood of harm is clearly and consistently
proportional to the extent of surgery, increasing progressively
from total thyroidectomy alone to concomitant unilateral and
finally bilateral central neck dissection. Moreover, the likeli-
hood of permanent morbidity resulting from routine pro-
phylactic central neck dissection may be higher in the hands of
less-experienced surgeons than is reported in published se-
ries by experienced high-volume surgeons. Given the lack of
measurable benefit and clear evidence of harm, prophylactic
central neck dissection cannot be routinely recommended.
Without evidence of collective benefit from routine prophy-
lactic central neck dissection, justification of a prophylactic
procedure for all is invalid. Rather, a needs-based paradigm
of performing a therapeutic procedure for the minority who
present with or subsequently develop clinically detectable
nodal metastasis appears most rational.
Evidence of Benefit? The evidence of mortality benefit
from central neck dissection for PTC is limited to one pub-
lished study with two significant limitations (17). The first
limitation is that no distinction was made between patients
undergoing therapeutic and prophylactic central neck dis-
section; thus conclusions cannot be made from this study re-
garding benefit of prophylactic central neck dissection. The
second limitation is with the validity of the mortality rate
comparison. The study by Tissel et al. (17) retrospectively
evaluated 195 patients from Sweden, of whom approximately
175 underwent pretracheal and paratracheal central neck
dissection and total or near-total thyroidectomy. Radioiodine
was administered in approximately 5% of patients. All-cause
mortality was reported as 26%, and disease-specific mortality
was 4%. Disease-specific mortality after exclusion of those
with distant metastasis at initial staging was reported as
1.6%. Comparison was made with two previously published
Scandinavian studies from Norway and Finland assessing
the utility of the then new TNM classification system, with
reported disease-specific mortality rates of 8.4% and 11%,
respectively (35, 36). No statistical comparison was made
between these mortality rates, but the authors concluded that
the differences were significant and due to routine central
neck dissection.
In the Norwegian study by Salvesen et al. (37) that specif-
ically assessed results from surgical treatment of the same
series of patients compared above (35), all-cause mortality in
PTC was reported to be 16% and disease-specific mortality to
be 9%. However, 12 of 15 patients who died from PTC had
only palliative operations because of initial extent of pri-
mary tumor (37). Exclusion of these 12 patients would give a
disease-specific mortality from PTC of 1.9% (3=155), which is
similar to that reported by Tissel et al. (17) of 1.6% after ex-
clusion of those with distant metastases at presentation. The
patients who underwent surgery with curative intent under-
went total or subtotal thyroidectomy with node plucking for
clinically detectable nodal metastasis, with approximately
40% of patients undergoing radioiodine therapy (37). Thus,
comparison of the outcomes from the Tissel et al. (17) study
and the Salvesen et al. study (37) addressing results of surgical
treatment reveal no obvious difference in disease-specific
mortality for those treated surgically with curative intent
(1.6% vs. 1.9%), although a much higher proportion of pa-
tients in the latter study underwent postoperative radioiodine
therapy (5% vs. 40%).
A comparison between the study from Finland by Kuk-
konen et al. (36) (1956–1979) and the study by Tissel et al. (17)
(1970–1989) is more problematic for the following two rea-
sons. First, the study period differed significantly between
these two, in contrast to the study periods of Salvesen et al.
(37) (1971–1989) and Tissel et al. (17) (1970–1989). Second, the
study by Kukkonen et al. (36) did not attempt to evaluate
the effect of surgery on survival. Data regarding extent of
thyroidectomy were limited, and data regarding node re-
moval and radioiodine therapy were not available or not
provided.
The recent study by Sywak et al. (22) is also used as evidence
supporting prophylactic CLND for PTC (11). This retro-
spective study reported a higher rate of undetectable post-
radioiodine-ablation TSH-stimulated thyroglobulin levels for
those undergoing total thyroidectomy with prophylactic uni-
lateral CLND (n¼ 56) (72%) than for those undergoing total
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thyroidectomy alone (n¼ 391) (43%, p< 0.001). However,
there were no significant differences reported in locoregional
recurrence rates (3.6% vs. 5.6%) or disease-specific mortality
rates (0% vs. 0%), despite significantly shorter median follow-
up duration (25 vs. 70 months) in the prophylactic CLND
group. Time-adjusted rates of recurrence to account for the
difference in duration of follow-up were not performed or
reported.
Two other studies have evaluated prophylactic CLND for
PTC without demonstrating evidence of lower recurrence or
mortality rates. The prospective study by Roh et al. (38) found
no significant difference in recurrence rate (4.1% and 1.2%,
respectively, p¼ 0.37) or disease-specific mortality rate (0%
and 0%) between those undergoing total thyroidectomy alone
(n¼ 73) and those undergoing total thyroidectomy with cen-
tral neck dissection (n¼ 82). A distinction was made between
patients undergoing CLND for therapeutic (n¼ 42) and pro-
phylactic (n¼ 40) reasons (38). The retrospective study by
Bardet et al. (33) demonstrated no significant difference in
recurrence rates for those without macroscopic nodal metas-
tasis (n¼ 427) who underwent total thyroidectomy alone
(3%), total thyroidectomy with bilateral central and lateral
neck dissection (0%), and total thyroidectomy with other node
dissection (5%, p¼ 0.12).
Evidence of Harm? There is a large body of evidence
documenting consistently greater morbidity rates for patients
undergoing CLND along with thyroidectomy than total thy-
roidectomy alone (22, 24, 33, 38–40). The reported complica-
tion rates are summarized in Table 1, with every study
demonstrating greater rates of temporary hypoparathyroid-
ism with central neck dissection. The extent of surgical treat-
ment of thyroid carcinoma is associated with a greater rate of
hypoparathyroidism when CLND is added to thyroidectomy
(41). Further study has demonstrated significantly higher
rates of hypoparathyroidism in patients undergoing bilateral
CLND than unilateral CLND, with no significant difference in
rates of undetectable thyroglobulin levels, recurrence, or
mortality (14, 42, 43).
Summary (Dr. Steward). Review of the current literature
finds no evidence of benefit in terms of lower recurrence or
mortality rates for thyroidectomy with prophylactic CLND
than for thyroidectomy without CLND for the management
of PTC, although clear and consistent evidence demonstrates
greater rates of transient hypoparathyroidism resulting from
prophylactic central neck dissection. As a result, utilitarian
justification for routine prophylactic central neck dissection is
invalid. A needs-based paradigm of therapeutic central neck
dissection appears to be the most reasonable. The concept of
distributive justice suggests that it is better overall for the
small minority of patients who subsequently develop central
nodal metastasis to undergo therapeutic reoperation by more
experienced central neck surgeons than for all patients to
undergo prophylactic operation, with the majority by less
experienced surgeons.
The apparent discordance between the relatively high
rates of occult nodal metastasis detected by prophylactic
central neck dissection and the relatively low rates of re-
currence after thyroidectomy without nodal dissection may
be related to postoperative radioiodine administration. The
sole justification for prophylactic CLND at this time may
be to subject patients to a greater risk of temporary hypo-
parathyroidism in hopes of avoiding risk from subsequent
radioiodine therapy for patients with pathologically negative
nodes to whom radioiodine would not be given otherwise.
In such cases, the additional risk of bilateral central dissec-
tion is unjustified. The validity of this paradigm requires
further study (44). Future study may also identify a subset of
higher-risk patients for whom prophylactic CLND may be
beneficial. This could include those diagnosed preopera-
tively with advanced T-stage or molecular mutations with
Table 1. Comparison of Reported Complication Rates Between Total Thyroidectomy
and Total Thyroidectomy with Central Neck Dissection in Various Studies
TT TTþCLND
Complication % P-Value Study
Recurrent laryngeal nerve injury
-Transient 4.1 7.3 0.39 Roh, 2008 (40)
1.3 5.4 0.06 Roh, 2007 (38)
1.0 1.8 0.62 Sywak, 2006 (22)
6.0 4.0 Henry, 1998 (24)
-Permanent 2.7 3.6 0.75 Roh, 2007 (38)
1.3 0 0.34 Palestini, 2008 (39)
1.0 0 0.45 Sywak, 2006 (22)
0 0 Henry, 1998 (24)
Hypoparathyroidism
-Transient 14 44 0.015 Roh, 2007 (38)
10 31 0.001 Palestini, 2008 (39)
13 27 0.003 Palestini, 2008 (39)
8 18 0.02 Sywak, 2006 (22)
8 14 Henry, 1998 (24)
-Permanent 0 5.0 0.06 Roh, 2007 (38)
2.7 0 0.20 Palestini, 2008 (39)
0.5 1.8 0.27 Sywak, 2006 (22)
0 4.0 Henry, 1998 (24)
TT, total thyroidectomy; TTþCLND, total thyroidectomy with central neck dissection.
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high risk of nonradioiodine avid nodal metastasis, muta-
tions of v-raf murine sarcoma viral oncogene homolog B1
(BRAF).
Summary
Ernest L. Mazzaferri, M.D., M.A.C.P.
It is important to recognize that the 10-year mortality rates
for PTC are low, in the range of 7%; however, the recurrence
rates are high with this disease, causing considerable anxiety
and morbidity for the patient. This is the main challenge in
managing the majority of patients with this disease. Prophy-
lactic neck dissection for small papillary carcinomas, which is
an important factor in reducing tumor burden, remains con-
troversial. The two summaries by Drs. Steward and Doherty
define the depth of the controversy over this aspect of man-
agement.
Dr. Steward makes the strong point that prophylactic
central compartment dissection cannot be justified based on a
high likelihood of finding tumor by removing subclinical
central compartment lymph-node metastases without using
the same argument for dissecting the ipsilateral lateral com-
partment, which has an equally high possibility of metastases.
The second point Dr. Steward argues is that careful analysis
of the literature fails to demonstrate evidence of benefit
measured in terms of enhanced survival or tumor recurrence,
which per se renders prophylactic surgery invalid. His third
major point is that the rates of permanent recurrent laryngeal
nerve injury and permanent hypoparathyroidism are as high
as 3.6% and 5%, respectively, with total thyroidectomy and
central lymph node compartment dissection. These argu-
ments provide little enthusiasm for routinely performing this
surgery.
Dr. Doherty makes the strong point that cervical lymph-
node metastases are found in as many as half the patients with
papillary cancer using standard pathology techniques, which
correlates with tumor persistence and recurrence and may be
associated with lower survival rates. The second point that
Dr. Doherty argues is that central compartment lymph-node
metastases cannot be accurately accessed before or during
surgery using preoperative ultrasonography or intraoperative
examination. The third important point is that, excluding
underpowered studies, there is some evidence to support
improvement in outcome with central compartment dissec-
tion, which in the hands of experienced surgeons is associated
with a 1% to 2% rate of permanent recurrent laryngeal nerve
injury and hypoparathyroidism, compared with much higher
complication rates with reoperation of the central neck com-
partment.
In many ways, the debate concerning prophylactic lymph-
node dissection is reminiscent of the widely divergent opin-
ions that prevailed for 30 years or more concerning the
efficacy and risk of total thyroidectomy for PTC (5, 8, 45–48)
until a study in 2007 by Bilimoria et al. (49) of 52,173 patients
found that total thyroidectomy results in significantly lower
recurrence rates and significantly higher survival rates for
PTCs of 1 cm or larger than with lobectomy, largely putting to
rest the arguments about the efficacy and safety of total thy-
roidectomy for PTCs of 1 cm or larger.
Conclusion (Dr. Mazzaferri). There seems little doubt that
cervical lymph-node metastases from PTC are common and
are not always entirely innocuous. Given the high odds of
leaving residual central compartment lymph-node metastases
by forgoing prophylactic lymph-node surgery, two options
are left for the patient: watchful waiting, which in some cases
may span decades, or empiric radioiodine therapy, which
may eradicate the thyroid remnant and smaller lymph-node
metastases. However, the efficacy of remnant ablation con-
tinues to be debated for small tumors, mainly because of the
small risk for radiation-induced second cancers, which ap-
pears to be 131I dose-dependent (50).
A recent study by Bonnet et al. (44) provides important
information concerning prophylactic neck compartment dis-
sections as it relates to the extent of initial surgery and the use
of postoperative 131I remnant ablation. Although 131I ablation
is not uniformly recommended for tumors smaller than
10 mm, its use is debated for papillary tumors between 10 and
20 mm in diameter. In a study from the Institut Gustave
Roussy, Bonnet et al. (44) retrospectively studied 115 patients
with PTCs of 2 cm or smaller without ultrasonographically
detectable cervical lymph-node metastases who were treated
with total thyroidectomy and complete prophylactic central
and ipsilateral lateral neck compartment dissection. Nearly
half (43%) the patients were found to have lymph-node me-
tastases. Radioiodine was not given to 42% of the patients
who had tumors smaller than 20 mm without lymph-node
metastases, whereas the remaining 58% were treated with 131I
if they had lymph-node metastasis, thyroid extracapsular
tumor invasion, or unfavorable histologic subtypes. Lymph-
node status played a major role in defining the indication
for 131I. Of the 30.5% of the cases classified as T1, 12 patients
had tumors smaller than 10 mm with lymph-node metastases
that were subsequently treated with 131I, whereas 13 others
with tumors 10 to 20 mm in diameter without lymph-node
metastases did not receive 131I therapy. Permanent vocal cord
paralysis occurred in 0.9%, and hypoparathyroidism occurred
in another 0.9% of the patients. After 1 year of follow-up,
cervical ultrasonography was normal in all patients, and re-
combinant human TSH-stimulated thyroglobulin was unde-
tectable in 97% of the patients. The authors concluded that
precise lymph-node staging produced using prophylactic
cervical lymph-node dissection for tumors initially staged as
T1N0* modified the indication for 131I ablation for 30% of the
patients.
Taken together, the role of prophylactic central and ipsi-
lateral lateral neck compartment dissections have a broad
effect on identifying the extent of locoregional lymph-node
metastases, a concept that must be examined within the
framework of potential complications and patient accep-
tance of extensive surgery for relatively low-grade tumors.
However, prophylactic surgery may help patients chose be-
tween small amounts of 131I (when it is necessary) in the range
of 30 to 50 mCi for remnant ablation that may well reduce the
rate of persistent or recurrent locoregional tumor to near zero.
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